Compare iShares MSCI Hong Kong ETF (EWH) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Smith & Nephew plc — how do they compare? iShares MSCI Hong Kong ETF trades at $22.09 (market cap $1.16B), while Smith & Nephew plc trades at $27.23 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 9.6× iShares MSCI Hong Kong ETF's market cap, and Smith & Nephew plc pays a 2.95% dividend while iShares MSCI Hong Kong ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 61 Days and Smith & Nephew plc for 121 Days on average.
| EWH | SNN | |
|---|---|---|
Market Cap | $1.16B | $11.10B |
Volume | 3,176,523 | 1,051,703 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $37.17 |
52-Week Low | $20.66 | $26.42 |
Typical Hold Time | 61 Days | 121 Days |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $22.06 with a 2.22% daily gain but maintains a bearish technical outlook. The ETF tracks Hong Kong equities, which face headwinds from Federal Reserve policy and US-Iran tensions, as the Hang Seng Index has declined over 11% from yearly highs. Moving averages signal strong bearish momentum while oscillators show neutral conditions, with key support at $21.
The outlook remains cautious given Hong Kong's sensitivity to US-China relations and Fed policy. Near-term performance hinges on geopolitical developments and Chinese economic data. Risks include continued institutional selling and Hang Seng volatility, but oversold conditions may attract contrarian buyers if tensions ease.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
